Loading
Life sciences · Journal article
International Microbiology · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an in vitro and cell-based exploratory study demonstrating antimicrobial and antibiofilm activity of Ocotea odorifera extract against three common clinical bacterial pathogens and anti-inflammatory potential comparable to meloxicam in cultured cells. The work is mechanistic and descriptive; the authors explicitly call for more in vivo investigation, and no human efficacy or safety data are provided.
In vitro antimicrobial and antibiofilm assays with phytochemical profiling and cell-based toxicity and anti-inflammatory evaluation. Clinical isolates of S. aureus, P. aeruginosa, and E. coli; BGM cultured mammalian cells.. Intervention: Ocotea odorifera extract. Compared with: Meloxicam (anti-inflammatory endpoint only); no comparator for antimicrobial or biofilm assays.
Extract active against planktonic cells of S. aureus, P. aeruginosa, and E. coli with MIC = 8 µg/mL Eradicated S. aureus biofilms at MBEC = 256 µg/mL; biofilm activity for other species not reported Phytochemical profiling identified erucamide as most abundant compound, described for this species for first time
Extract showed no cytotoxicity in BGM cells and anti-inflammatory activity comparable to meloxicam
This work offers preliminary evidence that O. odorifera may merit further investigation as a source of antimicrobial compounds, particularly for biofilm-associated infections. However, absence of in vivo efficacy data, pharmacokinetic properties, and direct comparison with established antimicrobials means the findings cannot yet guide clinical practice.
In vitro and cell-based study of a plant extract against clinical bacterial isolates with a single skin infection model, lacking human efficacy data or controlled comparison with standard antimicrobials; findings require in vivo confirmation.
As stated by the source record.
Quoted from the source exactly as published.
This work offers preliminary evidence that O. odorifera may merit further investigation as a source of antimicrobial compounds, particularly for biofilm-associated infections. However, absence of in vivo efficacy data, pharmacokinetic properties, and direct comparison with established antimicrobials means the findings cannot yet guide clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Exploring natural products in drug discovery can provide new options for effective treatments for infectious diseases. Biofilms are frequently not considered in most studies of antimicrobial activity, despite their relevance in microbial pathogenicity and resistance to antimicrobials. Here we investigated the antimicrobial and antibiofilm potentials of Ocotea odorifera, a Brazilian endangered species, against clinical isolates of Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli. We assessed the activity of the extract using minimal inhibitory concentration (MIC), minimal bactericidal concentration (MBC) and minimal biofilm eradication concentration (MBEC) assays, and a skin infection model. We evaluated the cytotoxicity of the extract in BGM cells and assessed its anti-inflammatory potential. Phytochemical profiling was conducted using classical methods and UHPLC-HRMS/MS. The extract was active against the planktonic cells of all species (MIC = 8 µg/mL, variable MBC values), and eradicated biofilms of S. aureus (MBEC = 256 µg/mL). Phytochemical analysis indicated that erucamide was the most abundant compound in the sample, which is being described for this species for the first time along with other phytomolecules. The extract did not show cytotoxicity and presented anti-inflammatory activity comparable to meloxicam. Our data provides evidence on the antimicrobial activity of O. odorifera, especially its antibiofilm potential, and highlights the need of preservation of endangered species as a valuable source of bioactive metabolites of clinical interest. More studies are necessary to investigate these pharmacological properties in vivo.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.